Measuring the Lifelong Impact of Cancer Treatment on Quality of Life
Compromises between length and quality of life should be informed by thorough research.
Progress Against Cancer
Compromises between length and quality of life should be informed by thorough research.
Paying attention to the social determinants of health will promote greater equity in cancer outcomes for all.
September is Childhood Cancer Awareness Month. Childhood cancer is relatively rare, but it is a devastating diagnosis that can ravage a family and create lifelong health challenges. In the United States, approximately 15,590 children...
Investigators present results from a phase III clinical trial of Trodelvy as a treatment for metastatic triple-negative breast cancer, and more news of the week from Cancer Today.
Pancreatic cancer is notoriously challenging to treat, due largely to the fact that the disease is often diagnosed after the cancer has metastasized. As a result, the five-year relative survival rate is just 10 percent....
Every September 24, World Cancer Research Day provides an opportunity to raise awareness about the important role research plays in improving cancer treatments and reducing the global burden of this devastating collection of diseases. ...
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report today. The report serves as an important record of the progress that has been made against cancer in the past year. Now in its 10th...
Supreme Court Justice Ruth Bader Ginsburg is not among us today. Sadly, we lost this iconic, trailblazing leader, who was the second woman to serve on the U.S. Supreme Court, and who was an inspiration and a...
The AACR issues an extensive report on cancer disparities, and more news of the week from Cancer Today.
Racial disparities in incidence and mortality exist for many cancers, prompting researchers to explore social and biological factors that could be responsible. John Carpten, PhD, of the University of Southern California’s Keck School of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More